X4 PHARMACEUTICALS, INC Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
X4 PHARMACEUTICALS, INC (XFOR) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$608.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was -$688.00K.
- X4 PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was $80.00K.
- X4 PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was $18.00K, a 99.33% decline year-over-year.
- X4 PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was $676.00K, a 63.73% decline year-over-year.
- X4 PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was -$12.78M.
- X4 PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was -$1.93M.
- X4 PHARMACEUTICALS, INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$7.07M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$688.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$608.00K 10-Q · filed 2026-08-06 | -$590.00K derived: sum of 3 quarters · filed 2026-08-06 | $86.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $80.00K 10-Q · filed 2026-05-06 | $98.00K derived: sum of 2 quarters · filed 2026-05-06 | $774.00K derived: sum of 3 quarters · filed 2026-05-06 | -$1.87M derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $694.00K derived: sum of 2 quarters · filed 2026-03-17 | -$1.95M derived: sum of 3 quarters · filed 2026-03-17 | -$12.78M 10-K · filed 2026-03-17 |
| 2025-09-30 | $676.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.97M derived: sum of 2 quarters · filed 2025-11-05 | -$12.80M 10-Q · filed 2025-11-05 | -$10.13M derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-06-30 | -$2.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$13.47M 10-Q · filed 2025-08-08 | -$10.80M derived: sum of 3 quarters · filed 2026-03-17 | -$8.94M derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-03-31 | -$10.83M 10-Q · filed 2025-05-01 | -$8.16M derived: sum of 2 quarters · filed 2026-03-17 | -$6.30M derived: sum of 3 quarters · filed 2026-03-17 | -$26.51M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.53M derived: sum of 2 quarters · filed 2026-03-17 | -$15.68M derived: sum of 3 quarters · filed 2026-03-17 | -$1.93M 10-K · filed 2026-03-17 |
| 2024-09-30 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$18.35M derived: sum of 2 quarters · filed 2024-11-13 | -$4.60M 10-Q · filed 2024-11-13 | -$10.93M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | -$20.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$6.46M 10-Q · filed 2024-08-08 | -$12.79M derived: sum of 3 quarters · filed 2026-03-17 | -$37.95M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $13.76M 10-Q · filed 2024-05-07 | $7.42M derived: sum of 2 quarters · filed 2026-03-17 | -$17.74M derived: sum of 3 quarters · filed 2026-03-17 | $12.12M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$6.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$31.50M derived: sum of 2 quarters · filed 2026-03-17 | -$1.64M derived: sum of 3 quarters · filed 2026-03-17 | -$7.07M 10-K · filed 2026-03-17 |
| 2023-09-30 | -$25.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.70M derived: sum of 2 quarters · filed 2023-11-09 | -$743.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $29.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $24.42M 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | -$5.44M 10-Q · filed 2023-05-04 | |||
| 2022-09-30 | -$3.01M 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | -$511.00K 10-Q · filed 2022-08-04 | -$687.00K derived: sum of 2 quarters · filed 2022-08-04 | ||
| 2022-03-31 | -$176.00K 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | $36.00K 10-Q · filed 2021-11-04 | $9.00K derived: sum of 2 quarters · filed 2021-11-04 | $39.00K derived: sum of 3 quarters · filed 2021-11-04 | |
| 2021-06-30 | -$27.00K 10-Q · filed 2021-08-03 | $3.00K derived: sum of 2 quarters · filed 2021-08-03 | ||
| 2021-03-31 | $30.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |